Tuberculosis-related mortality in people living with HIV in Europe and Latin America: An international cohort study

The Lancet HIV

Volumn 3, Issue 3, 2016, Pages e120-e131

  Podlekareva, Daria N ^a   Efsen, Anne Marie W ^a   Schultze, Anna ^b   Post, Frank A ^c   Skrahina, Alena M ^d   Panteleev, Alexander ^e   Furrer, Hansjakob ^f   Miller, Robert F ^g   Losso, Marcelo H ^h   Toibaro, Javier ^h   Miro, Jose M ⁱ   Vassilenko, Anna ^j,k   Girardi, Enrico ^l   Bruyand, Mathias ^m   Obel, Niels ^a   Lundgren, Jens D ^a   Mocroft, Amanda ^b   Kirk, Ole ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d National Research and Practical Centre for Pulmonology and Tuberculosis   (Belarus)

^e TB Hospital 2   (Russian Federation)

^f UNIVERSITY OF BERN   (Switzerland)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h HOSPITAL RAMOS MEJÍA   (Argentina)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j BELARUSIAN STATE MEDICAL UNIVERSITY   (Belarus)

^k Hospital of Infectious Diseases   (Belarus)

^l NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^m INSERM   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMYCIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TUBERCULOSTATIC AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG SENSITIVITY; EUROPE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SOUTH AND CENTRAL AMERICA; TUBERCULOSIS; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; COMPLICATION; EPIDEMIC; HIV INFECTIONS; MIDDLE AGED; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; COHORT STUDIES; EPIDEMICS; EUROPE; FEMALE; HIV INFECTIONS; HUMANS; LATIN AMERICA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84959211106     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(15)00252-0     Document Type: Article

References (27)

1. DeHovitz J, Uuskula A, El-Bassel N The HIV epidemic in Eastern Europe and Central Asia. Curr HIV/AIDS Rep 2014, 11:168-176.
2. Global tuberculosis report 2014 2014, WHO, World Health Organization, Geneva.
3. Mocroft A, Lundgren JD, Sabin ML, et al. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med 2013, 10:e1001510.
4. Podlekareva DN, Mocroft A, Post FA, et al. Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. AIDS 2009, 23:2485-2495.
5. Pimpin L, Drumright LN, Kruijshaar ME, et al. Tuberculosis and HIV co-infection in European Union and European Economic Area countries. Eur Respir J 2011, 38:1382-1392.
6. Raykhert I, Miskinis K, Lepshyna S, et al. HIV seroprevalence among new TB patients in the civilian and prisoner populations of Donetsk Oblast, Ukraine. Scand J Infect Dis 2008, 40:655-662.
7. ECDC and WHO/Europe joint report on tuberculosis surveillance and monitoring in Europe. Euro Surveill 2014, 19:20741. Eurosurveillance Editorial Team.
8. Efsen AM, Schultze A, Post F, et al. Major challenges in clinical management of TB/HIV co-infected patients in Eastern Europe compared with Western Europe and Latin America. PLoS One 2015, 10:e0145380.
9. Post FA, Grint D, Werlinrud AM, et al. Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe. J Infect 2014, 68:259-263.
10. Mansfeld M, Skrahina A, Shepherd L, et al. Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe. HIV Med 2015, 16:544-552.
11. Podlekareva DN, Panteleev AM, Grint D, et al. Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. Eur Respir J 2014, 43:166-177.
12. Kowalska JD, Friis-Moller N, Kirk O, et al. The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology 2011, 22:516-523.
13. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012, 39:1425-1431.
14. Falzon D, Jaramillo E, Wares F, Zignol M, Floyd K, Raviglione MC Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. Lancet Infect Dis 2013, 13:690-697.
15. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013, 42:156-168.
16. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009, 9:153-161.
17. Lange C, Abubakar I, Alffenaar J-WC, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014, 44:23-63.
18. Bastos ML, Hussain H, Weyer K, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis 2014, 59:1364-1374.
19. Lawn SD, Mwaba P, Bates M, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013, 13:349-361.
20. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011, 365:1482-1491.
21. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011, 365:1492-1501.
22. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011, 365:1471-1481.
23. Kherosheva T, Thorpe LE, Kiryanova E, et al. Encouraging outcomes in the first year of a TB control demonstration program: Orel Oblast, Russia. Int J Tuberc Lung Dis 2003, 7:1045-1051.
24. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011, 38:516-528.
25. Zaller N, Mazhnaya A, Larney S, et al. Geographic variability in HIV and injection drug use in Ukraine: implications for integration and expansion of drug treatment and HIV care. Int J Drug Policy 2015, 26:37-42.
26. Mocroft A, Kirk O, Aldins P, et al. Loss to follow-up in an international, multicentre observational study. HIV Med 2008, 9:261-269.
27. Lönnroth K, Migliori G B, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015, 45:928-952.